Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
|
| Abstract |
The purpose of this study was to clarify the efficacy and safety of docetaxel and cisplatin as second-line treatment for patients with S-1 refractory advanced gastric cancer. Between 1999 and 2006, 32 patients received docetaxel (60 mg/m²) and cisplatin (60 mg/m²) (Dp regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable toxicity was detected. The overall response rate was 21.9%. Seven patients showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were leukopenia and neutropnea. Non-hematological toxicities were generally mild to moderate and controllable. this study showed satisfactory therapeutic outcomes for patients with gastric cancer refractory to S- 1 chemotherapy.
|
|---|---|
| Authors | R Takagawa, C Kunisaki, H Makino, Y Nagano, S Fujii, J Kimura, T Kosaka, H A Ono, H Akiyama, I Endo |
| Journal | Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 23 Issue 1 Pg. 44-8 (Feb 2011) ISSN: 1973-9478 [Electronic] England |
| PMID | 21482495 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!